Leto Laboratories is a world leading biotech in anti-tumor cytokine drug development with the broadest anti-tumor cytokine pipelines and the largest number of related patents in China. The leading asset LTC004 is in the Phase I clinical study in China and the United States, the fastest advanced druggable cytokine in China with global-leading dosage administration. The proprietary protein renaturation technology break through existing patent barriers and provide significant cost leadership. Leto Labs was established in Beijing in 2014. Core team all comes from the leading pharmaceutical companies, Novo Nordisk and Johnson & Johnson, etc., with an average of 15+ years of industry and R&D experience. At present, Leto Labs completed multiple rounds of financing, and has partnered with a number of leading pharma with tech-transfer/out-licensing of more than 10 projects.